JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (12): 51-56.doi: 10.6040/j.issn.1671-7554.0.2015.253

Previous Articles     Next Articles

Expression of chemokine CXCL16 and its receptor CXCR6 can be suppressed by rcombinant human TNF receptor α Ⅱ-Ig fusion protein in ankylosing spondylitis

ZHANG Peiyi1, ZHOU Shufen2, WANG Meiying2, LEI Zhenhua2, WENG Junxiong2, TIAN Ye2, PENG Xin2, FU Biling2, DENG Liuxia2, ZOU Shihai2, GUO Chengshan1,2   

  1. 1. Department of Hematology, Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    2. Department of Rheumatology, Shenzhen Baoan Hospital Affiliated to Southern Medical University, Shenzhen 518101, Guangdong, China
  • Received:2015-03-09 Online:2015-12-10 Published:2015-12-10

PDF (PC)

208

Abstract: Objective To investigate the role of CXCL16/CXCR6 in the pathogenesis of ankylosing spondylitis (AS) and the functional mechanism of recombinant human TNF receptor-αⅡ-Ig fusion protein (rhTNFR:Fc). Methods The subjects were divided into AS active group, AS treated group and healthy control group. The levels of receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG) and CXCL16 in serum and CXCL16, CXCR6 mRNA in peripheral blood cells (PBMC) were detected with enzyme-linked immunosorbent assay (ELISA) and fluorescent quatitative PCR. The proliferation of lymphocytes and the level of RANKL in supernatant stimulated by different concentrations (40 ng/mL, 80 ng/mL) of rhCXCL16 were assessed with CCK-8 and ELISA. Results ① The clinical response rate in the AS active group reached 95.45%, and indicators including ESR, CRP, BASDAI, BASFI, spinal pain and nocturnal pain in AS treated group were significantly reduced compared with those in AS active group (all P<0.05). ② Serum RANKL level, RANKL/OPG ratio, and CXCLl6 level in AS active group were significantly higher than those in the healthy control group; CXCLl6 and CXCR6 mRNA levels in AS active group were both significantly higher than those in healthy control group and AS treated group (all P<0.05). ③ In the AS active group, stimulated by CXCLl6(40 ng/mL, 80 ng/mlL), the proliferation of lymphocytes and the level of RANKL in the supernatant were significantly higher (all P<0.05). ④ In the AS active group, the serum CXCL16 was positively correlated to RANKL, RANKLL/OPG radio, CRP and ESR (all P<0.05). Conclusion CXCL16/CXCR6 may play an important role in the pathogenesis of AS.Besides, rhTNFR:Fc could reduce the expression of CXCL16/CXCR6, which may be one of the mechanisms in inhibiting inflammation and bone destruction.

Key words: Osteoprotegerin, Ankylosing spondylitis, Chemokine CXCL16, Chemokine receptor CXCR6, Receptor activator of nuclear factor κB-ligand

CLC Number: 

  • R593.23
[1] 徐愿,阎小萍,张文健.补肾强督方含药血清对强直性脊柱炎OPG/RANKL通路的作用[J].中国中西医结合杂志, 2012, 32(4):521-524. XU Yuan, YAN Xiaoping, ZHANG Wenjian. The function of bushen qiangdu recipe containing serum in OPG/RANKL pathway of ankylosing spondylitis patients[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2012, 32(4):521-524.
[2] Yilmaz S, Cinar M, Pekel A, et al. The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with Behcet's disease[J]. Clin Exp Rheumatol, 2013, 31(3 suppl 77):84-87.
[3] Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook:a guide to assess spondyloarthritis[J]. Ann Rheum Dis, 2009, 68:Suppl 2:ii1-44.. doi:10.1136/ard.2008.104018.
[4] Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general[J]. Ann Rheum Dis, 2011, 70(1):25-31.
[5] Chen CH, Chen HA, Liao HT, et al. Soluble receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis:OPG is associated with poor physical mobility and reflects systemic inflammation[J]. Clin Rheumatol, 2010, 29(10):1155-1161.
[6] Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-κB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis[J]. Rheumatology, 2006, 45(10):1197-1200.
[7] 赵伟,黄烽.细胞核因子κB受体活化因子配基在强直性脊柱炎的表达及意义[J].解放军医学杂志, 2004, 29(6):482-485. ZHAO Wei, HUANG Feng. The role of RANKL in the pathogenesis of peripheral joint bone destruction in ankylosing spondylitis[J]. Medical Journal of Chinese People's Liberation Army, 2004, 29(6):482-485.
[8] La Porta CA. Thoughts about cancer stem cells in solid tumors[J]. World J Stem Cells, 2012, 4(3):17-20.
[9] 庄宇,简怡娜,谭志明.趋化因子CXCL16与系统性红斑狼疮的研究进展[J].中外医学研究, 2012, 10(6):146-148. ZHUANG Yu, JIAN Yina, TAN Zhiming. The research progress of chemolines CXCL16 and systemic lupus erythematosus[J]. Chinese and Foreign Medical Research, 2012, 10(6):146-148.
[10] Kawai T, Matsuyama T, Hosokawa Y, et al. B and T Lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease[J]. American Journal of Pathology, 2006, 169(3):987-998.
[11] Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand[J]. Nature, 1999, 402(6759):304-309.
[12] Baraliakos X, Brmdt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept:clinical and magnetic resonance imaging data[J]. Arthritis Rheum, 2005, 53(6):856-863.
[13] Braun J, McHugh N, Singh A, et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25mg twice-weekly[J]. Rheumatology, 2007, 46(6):999-1004.
[14] Lee SH, Lee YA, Hong SJ, et al. Etanercept 25mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean Patients[J]. Clin Rheumatol, 2008, 27(2):179-181.
[15] Lee J, Noh JW, Hwang JW, et al. Extended dosing of etanercept 25mg can be effective in patients with ankylosing spondylitis:a retrospective analysis[J]. Clin Rheumatol, 2010, 29(10):1149-1154.
[16] Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, et al. Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis[J]. Patient Preference and Adherence, 2013, 7:961-972.
[1] WANG Liya, MA Zhenzhen, YANG Qingrui. Association between PTGER4 gene polymorphism and susceptibility of ankylosing spondylitis in Han population in Shandong Province [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(6): 31-34.
[2] QIAO Zhen1, QI Caihui1, YANG Meizi2, JIN Yongjun1. Effect of α-melanocyte stimulating hormone on the expressions of OPG and  RANKL mRNA in mouse osteoblasts [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(3): 56-58.
[3] XIA Yu1， WANG Lai-cheng1， SUN Hui1， TANG Hong-wei2， MA Chun-yan1， CUI Bin1， ZHAO Yue-ran1. Association of polymorphisms in the ERAP1 gene with ankylosing spondylitis in the Han Chinese population [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(10): 127-130.
[4] ZHAO Lijian, HAN Bo, ZHANG Liping, ZHANG Yi, ZHANG Jianjun. Clinical evaluation of serum osteoprotegerin in diagnosis of coronary artery lesions of Kawasaki disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(1): 116-119.
[5] LIU Wen-guang,WANG Shao-jin,WANG Xing-shan,DUAN Yuan-tao,LIU Sheng-hou. Effect of total hip arthroplasty in ankylosing spondylitis with tetanic deformity of the hip [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(2): 192-195.
[6] DING Shou-ling,XIA Ming,ZHANG Han-bing,ZHANG Ju-hong,YANG Ying,LIU Fang,XU An-ting. Expression and significance of nuclear factor-kappa B ligand and osteoprotegerin in cholesteatoma tissues [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(10): 1034-1037.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd